Showing 1 to 3 of 3 results


19-Year Remission Achieved in Neuroblastoma Patient Treated with CAR-T Cells
A 4-year-old girl treated for neuroblastoma in 2006 at Texas Children's Hospital with experimental CAR-T cell therapy remains cancer-free 19 years later, representing the longest remission ever reported for this treatment and offering new hope for solid tumor therapies.
19-Year Remission Achieved in Neuroblastoma Patient Treated with CAR-T Cells
A 4-year-old girl treated for neuroblastoma in 2006 at Texas Children's Hospital with experimental CAR-T cell therapy remains cancer-free 19 years later, representing the longest remission ever reported for this treatment and offering new hope for solid tumor therapies.
Progress
48% Bias Score


18-Year Cancer Remission Achieved with First-Generation CAR-T Therapy in Neuroblastoma Patient
An 18-year cancer remission in a neuroblastoma patient treated with first-generation CAR-T cell therapy at age four has been reported, exceeding previous remission records for both hematological and solid cancers, highlighting the therapy's potential for broader applications.
18-Year Cancer Remission Achieved with First-Generation CAR-T Therapy in Neuroblastoma Patient
An 18-year cancer remission in a neuroblastoma patient treated with first-generation CAR-T cell therapy at age four has been reported, exceeding previous remission records for both hematological and solid cancers, highlighting the therapy's potential for broader applications.
Progress
44% Bias Score

18-Year Remission Achieved in Neuroblastoma Patient via CAR T-cell Therapy
An 18-year remission in a neuroblastoma patient treated with CAR T-cell therapy, a pioneering immunotherapy involving genetically modified T-cells, showcases its potential for long-term remission in solid tumors, particularly for childhood cancers.

18-Year Remission Achieved in Neuroblastoma Patient via CAR T-cell Therapy
An 18-year remission in a neuroblastoma patient treated with CAR T-cell therapy, a pioneering immunotherapy involving genetically modified T-cells, showcases its potential for long-term remission in solid tumors, particularly for childhood cancers.
Progress
40% Bias Score
Showing 1 to 3 of 3 results